Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab (vol 115, pg 71, 2018)

被引：3
|
作者：
Sato, Koichi [1 ]
Akamatsu, Hiroaki [1 ]
Murakami, Eriko [1 ]
Sasaki, Seigo [1 ]
Kanai, Kuninobu [1 ]
Hayata, Atsushi [1 ]
Tokudome, Nahomi [1 ]
Akamatsu, Keiichiro [1 ]
Koh, Yasuhiro [1 ]
Ueda, Hiroki [1 ]
Nakanishi, Masanori [1 ]
Yamamoto, Nobuyuki [1 ]
机构：
[1] Wakayama Med Univ, Dept Internal Med 3, Wakayama, Japan
来源：
LUNG CANCER | 2018年 / 126卷
关键词：
D O I：
10.1016/j.lungcan.2018.11.007
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：230 / 231
页数：2
相关论文
共 50 条
  • [41] The gut microbiome, immune check point inhibition and immune-related adverse events in non-small cell lung cancer
    Bredin, Philip
    Naidoo, Jarushka
    CANCER AND METASTASIS REVIEWS, 2022, 41 (02) : 347 - 366
  • [42] Predictive Factors Correlated with the Development of Immune-Related Adverse Events in Patients with Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors
    Sonehara, Kei
    Tateishi, Kazunari
    Araki, Taisuke
    Komatsu, Masamichi
    Akahane, Jumpei
    Yamamoto, Hiroshi
    Hanaoka, Masayuki
    CANCER MANAGEMENT AND RESEARCH, 2022, 14 : 427 - 435
  • [43] Immune-Related Adverse Events in Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibition in Combination With Chemotherapy: A Brief Report
    Shantzer, Lindsey B.
    Dougherty, Sean C.
    Bolte, Fabian
    Melson, John W.
    Reed, Daniel R.
    Lynch, Alia C.
    Gentzler, Ryan D.
    Novicoff, Wendy
    Hall, Richard D.
    CLINICAL LUNG CANCER, 2022, 24 (02) : e60 - e64
  • [44] Correction to: Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort
    Abdul Rafeh Naqash
    Biagio Ricciuti
    Dwight H. Owen
    Vaia Florou
    Yukihiro Toi
    Cynthia Cherry
    Maida Hafiz
    Andrea De Giglio
    Mavish Muzaffar
    Sandip H. Patel
    Shunichi Sugawara
    Jarred Burkart
    Wungki Park
    Rita Chiari
    Jun Sugisaka
    Gregory A. Otterson
    Gilberto de Lima Lopes
    Paul R. Walker
    Cancer Immunology, Immunotherapy, 2020, 69 : 1189 - 1189
  • [45] Predictive value of immune-related adverse events during pembrolizumab treatment in non-small cell lung cancer
    Valencia Soto, Carmen Maria
    Villacanas Palomares, Maria Victoria
    Garcia-Avello Fernandez-Cueto, Adela
    Barbadillo Villanueva, Sara
    Martinez Callejo, Virginia
    Ochagavia Sufrategui, Maria
    Munoz Cacho, Pedro
    Valero Dominguez, Marta
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2024, 31 (01) : 40 - 45
  • [46] Risk factors and predictors of immune-related adverse events: implications for patients with non-small cell lung cancer
    Issa, Majd
    Tang, Joy
    Guo, Yizhen
    Coss, Chris
    Mace, Thomas A.
    Bischof, Jason
    Phelps, Mitch
    Presley, Carolyn J.
    Owen, Dwight H.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (08) : 861 - 874
  • [47] Association of early immune-related adverse events with treatment efficacy of neoadjuvant Toripalimab in resectable advanced non-small cell lung cancer
    Tao, Ye
    Li, Xiang
    Liu, Bing
    Wang, Jia
    Lv, Chao
    Li, Shaolei
    Wang, Yuzhao
    Chen, Jinfeng
    Yan, Shi
    Wu, Nan
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [48] Immune related adverse events (irAE) and disease response with nivolumab in pre-treated advanced non-small cell lung cancer (NSCLC)
    Connolly, E.
    Mallesara, G.
    Nordman, I.
    ANNALS OF ONCOLOGY, 2017, 28
  • [49] Immune-related adverse events and nivolumab outcomes in non-small cell lung cancer patients: A multi-institutional, retrospective cohort study.
    Moor, Rebecca Jane
    Roberts, Kate Elizabeth
    Mason, Robert
    Gunawan, Ben
    Feng, Sophie
    Hong, Jun Hee
    Von Itzstein, Mitchell
    Hughes, Brett Gordon Maxwell
    Lwin, Zarnie
    Jain, Vikram Kumar
    Bigby, Kieron James
    Azer, Mary W. F.
    Sanmugarajah, Jasotha
    O'Byrne, Kenneth John
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [50] Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients
    Remon, Jordi
    Mezquita, Laura
    Corral, Jesus
    Vilarino, Noelia
    Reguart, Noemi
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S1516 - S1533
12345